Infectious diseases are a leading cause of morbidity and mortality worldwide with vaccines
playing a critical role in preventing deaths. To better understand the impact of low …

Background Achieving polio eradication requires ensuring the delivery of sufficient supplies
of the right vaccines to the right places at the right times. Despite large global markets …

Background The COVID-19 pandemic has contributed to the widespread disruption of
immunization services, including the postponement of mass vaccination campaigns …

Poliomyelitis is the leading infectious cause of acute flaccid paralysis among children under
five years of age, caused by the Wild Poliovirus, with no medical cure other than prevention …

Introduction Detection of poliovirus transmission and ongoing oral poliovirus vaccine (OPV)
use continue to delay poliomyelitis eradication. In 2016, the Global Polio Eradication …

Despite exhaustive and fully-financed plans to manage the risks of globally coordinated
cessation of oral poliovirus vaccine (OPV) containing type 2 (OPV2) prior to 2016, as of …

Due to the very low, but nonzero, paralysis risks associated with the use of oral poliovirus
vaccine (OPV), eradicating poliomyelitis requires ending all OPV use globally. The Global …

Background There have been declines in global immunisation coverage due to the COVID-
19 pandemic. Recovery has begun but is geographically variable. This disruption has led to …

Background Investments in national immunization programs and the Global Polio
Eradication Initiative (GPEI) have resulted in substantial reductions in paralytic polio …

Abstract In May 2016, the Global Polio Eradication Initiative (GPEI) coordinated the
cessation of all use of type 2 oral poliovirus vaccine (OPV2), except for emergency outbreak …